Hologic, Inc. (NASDAQ:HOLX) Given Average Rating of “Moderate Buy” by Brokerages

Hologic, Inc. (NASDAQ:HOLX) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $85.73.

Several equities research analysts have recently commented on HOLX shares. Stephens started coverage on shares of Hologic in a research report on Thursday. They set an “overweight” rating and a $87.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Friday, May 3rd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their target price for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Evercore ISI upped their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic in the 4th quarter valued at about $27,000. iA Global Asset Management Inc. bought a new position in Hologic in the 1st quarter worth approximately $37,000. Massmutual Trust Co. FSB ADV grew its stake in Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 227 shares in the last quarter. Allworth Financial LP raised its holdings in Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 179 shares during the period. Finally, Mather Group LLC. purchased a new stake in shares of Hologic during the first quarter worth $48,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of Hologic stock opened at $74.25 on Friday. The business has a 50-day simple moving average of $74.32 and a 200 day simple moving average of $74.30. Hologic has a one year low of $64.02 and a one year high of $82.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. The firm has a market capitalization of $17.33 billion, a price-to-earnings ratio of 37.88, a PEG ratio of 2.47 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company posted $1.06 earnings per share. The company’s quarterly revenue was down .8% on a year-over-year basis. On average, research analysts anticipate that Hologic will post 4.08 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.